Skip to main content
SpringerLink
Log in
Book cover

Restless Legs Syndrome/Willis Ekbom Disease pp 155–167Cite as

Augmentation: Criteria, Prevalence, and Differential Diagnosis

  • Chapter
  • First Online:

  • 617 Accesses

Abstract

Since the first studies of dopaminergic agents for the treatment of RLS/WED in the early 1980s [1], the overall long-term efficacy of these drugs has been well established by further clinical trials [2–4], and the reported adverse events have been generally mild. Furthermore, unlike in Parkinson’s disease, no cases of dyskinesia have been ever reported [3].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol. 1982;39:739.

    Article  CAS  PubMed  Google Scholar 

  2. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol. 2012;19:1385–96.

    Article  PubMed  Google Scholar 

  3. Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675–84.

    Article  PubMed  Google Scholar 

  4. Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621–31.

    Article  CAS  PubMed  Google Scholar 

  5. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205–13.

    Article  CAS  PubMed  Google Scholar 

  6. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.

    Article  PubMed  Google Scholar 

  7. Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007;8:520–30.

    Article  PubMed  Google Scholar 

  8. Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10:710–20.

    Article  CAS  PubMed  Google Scholar 

  9. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med. 2007;8:742–52.

    Article  PubMed  Google Scholar 

  10. Allen RP. Pregabalin versus pramipexole for restless legs syndrome. N Engl J Med. 2014;370:2050–1.

    CAS  PubMed  Google Scholar 

  11. Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.

    Article  PubMed  Google Scholar 

  12. Allen RP, Ondo WG, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12:431–9.

    Article  PubMed  Google Scholar 

  13. Garcia-Borreguero D, Högl B, Ferini Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in Restless Legs Syndrome: Results from a prospective, multicenter study over sixty-six weeks. Mov Disord. 2011, in press.

    Google Scholar 

  14. Benes H, Heinrich CR, Ueberall MA, Kohnen R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep. 2004;27:674–82.

    Article  PubMed  Google Scholar 

  15. Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5:9–14.

    Article  PubMed  Google Scholar 

  16. Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med. 2002;3(Suppl):S23–5.

    Article  PubMed  Google Scholar 

  17. Vetrugno R, La Morgia C, D’Angelo R, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord. 2007;22:424–7.

    Article  PubMed  Google Scholar 

  18. Trenkwalder C, Benes H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–50.

    Article  CAS  PubMed  Google Scholar 

  19. Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome: the scope of the problem. Sleep Med. 2011;12:425–6.

    Article  PubMed  Google Scholar 

  20. Garcia-Borreguero D, Benitez A, Kohnen R, Allen R. Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment. Postgrad Med. 2015;127:716–25.

    Article  PubMed  Google Scholar 

  21. Trenkwalder C, Benes H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord. 2007;22:696–703.

    Article  PubMed  Google Scholar 

  22. Högl B, Garcia-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol. 2010;257:230–7.

    Article  PubMed  Google Scholar 

  23. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008;7:595–604.

    Article  CAS  PubMed  Google Scholar 

  24. Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25:1675–83.

    Article  PubMed  Google Scholar 

  25. Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10:710–20.

    Article  CAS  PubMed  Google Scholar 

  26. Benes H, Garcia-Borreguero D, Ferini-Strambi L, Schollmayer E, Fichtner A, Kohnen R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 2012;13:589–97.

    Article  PubMed  Google Scholar 

  27. Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 2008;9:572–4.

    Article  PubMed  Google Scholar 

  28. Cano N, Bayarri P, Chilet R, Plaza G, Carrasco A, Ibanez J. Evolution of safety profile of different therapeutic alternatives in restless legs syndrome (rls). Sleep Med 2013;14S:e88 (abstract).

    Google Scholar 

  29. Inoue Y, Hirata K, Hayashida K, Hattori N, Tomida T, Garcia-Borreguero D. Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2013;40:326–33.

    Article  CAS  PubMed  Google Scholar 

  30. Miranda C. Transdermal Rotigotine in the treatment of restless legs patients who develop augmentation of symptoms. Rev Méd Chile. 2013;141:407–8.

    Article  Google Scholar 

  31. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord. 2006;21:1627–35.

    Article  PubMed  Google Scholar 

  32. Garcia-Borreguero D, Hogl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012;27:277–83.

    Article  CAS  PubMed  Google Scholar 

  33. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol. 2000;7(Suppl 1):27–31.

    Article  PubMed  Google Scholar 

  34. Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep. 2003;26:819–21.

    Article  PubMed  Google Scholar 

  35. Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord. 2006;21:1404–10.

    Article  PubMed  Google Scholar 

  36. Inoue Y, Kuroda K, Hirata K, Uchimura N, Kagimura T, Shimizu T. Long-term open-label study of pramipexole in patients with primary restless legs syndrome. J Neurol Sci. 2010;294:62–6.

    Article  CAS  PubMed  Google Scholar 

  37. Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med. 2011;12:34–40.

    Article  PubMed  Google Scholar 

  38. Högl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12:351–60.

    Article  PubMed  Google Scholar 

  39. Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13:1280–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sleep Research Institute, Paseo de la Habana 151, 28036, Madrid, Spain

    Diego García-Borreguero, Mauro Manconi & Luigi Ferini-Strambi

Authors
  1. Diego García-Borreguero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mauro Manconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luigi Ferini-Strambi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diego García-Borreguero .

Editor information

Editors and Affiliations

  1. Sleep and Epilepsy Center, Neurocenter of Southern Switzerland, Civic Hospital, Lugano, Switzerland

    Mauro Manconi

  2. Sleep Research Institute, Madrid, Spain

    Diego García-Borreguero

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this chapter

Cite this chapter

García-Borreguero, D., Manconi, M., Ferini-Strambi, L. (2017). Augmentation: Criteria, Prevalence, and Differential Diagnosis. In: Manconi, M., García-Borreguero, D. (eds) Restless Legs Syndrome/Willis Ekbom Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-6777-3_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6777-3_12

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-6775-9

  • Online ISBN: 978-1-4939-6777-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation